Physician profile
James W Cutcliffe
NPI 1912318981
$5,944.42
in general payments reported to CMS, 2019-2025
26 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $406 · 2021: $462 · 2022: $469 · 2023: $1,235 · 2024: $1,769 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708 · Travel and Lodging: $1,476 · Gift: $24.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.32 |
| Travel and Lodging | $1,476.17 |
| Gift | $24.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,374.12 | 2019-2025 | Da Vinci Surgical System |
| Abbvie INC. | $317.43 | 2019-2025 | |
| Endomagnetics LTD | $259.03 | 2023 | Magtrace, Magseed |
| Ethicon US, LLC | $205.21 | 2019-2025 | Surgicel Nu-Knit, Vistaseal, Evarrest |
| Lucid Diagnostics INC. | $113.46 | 2022 | |
| Conmed Corporation | $76.48 | 2023 | Airseal, Visiclear |
| Artivion, INC. | $56.46 | 2024-2025 | Photofix Decellularized Bovine Pericardium, Vascular, Bioglue Surgical Adhesive |
| Tela Bio, INC. | $55.06 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Davol INC. | $52.37 | 2023-2024 | Arista Ah Flexitip, Phasix Mesh |
| Angiodynamics, INC. | $46.14 | 2019 | |
| Innocoll Pharmaceuticals Limited | $43.78 | 2021-2022 | |
| Acera Surgical, INC. | $37.90 | 2019-2024 | Restrata Wound Matrix |
| W. L. Gore & Associates, INC. | $36.72 | 2023-2025 | Gore Tag Conformable Thoracic Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control |
| E.R. Squibb & Sons, L.L.C. | $26.66 | 2021 | |
| Elucent Medical | $26.37 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $25.83 | 2019-2021 | |
| Integra Lifesciences Corporation | $24.59 | 2024 | Integra, Surgimend, Omnigraft |
| Allergan, INC. | $22.62 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.30 | 2024 | Myrisk |
| Kowa Pharmaceuticals America, INC. | $20.58 | 2023 | Seglentis |
| Incyte Corporation | $19.84 | 2019 | |
| Cardinal Health 414 LLC | $18.42 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $16.84 | 2021 | |
| Polynovo North America LLC | $16.12 | 2022 | |
| Medtronic, INC. | $15.72 | 2023 | Signia |
| Ossur Americas, INC. | $15.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cutcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.